Focal Segmental Glomerulosclerosis Following Nuvavxovid COVID-19 Vaccine: A Case Report and Literature Review

10.6221/AN.202409_38(3).0006

Po-Chuan Yu；Kuo-Cheng Lu；Szu-Han Lin；Ching-Hsiu Peng

SARS-CoV-2 ； COVID-19 vaccines ； recombinant protein ； nephrotic syndrome ； focal segmental glomerulosclerosis ； steroid

Acta Nephrologica

38卷3期（2024 / 09 / 01）

194 - 200

英文

Nephrotic syndrome after COVID-19 vaccination is an uncommon complication. It was only reported in patients receiving viral vector or mRNA COVID-19 vaccines from current literature. We report a case of a 30-year-old male developing nephrotic syndrome after COVID-19 vaccination (Nuvavxovid®, recombinant protein vaccine) with biopsy-proven pathologic diagnosis of focal segmental glomerulosclerosis. We assumed that the nephrotic syndrome in this patient was most likely attributed to COVID-19 vaccination from the timeline and the serologic workup. After diagnosis, this patient started to receive a standard dose of oral prednisolone (1 mg/kg/day). Diuresis with urine bubble disappearance was noted 8 days after steroid therapy was initiated. Complete remission of his nephrotic syndrome was achieved thereafter. He remained in remission after 1 year since steroid initiation.